Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torametinib for Recurrent/Refractory Pediatric MAPK-Pathway Related Tumors
ChiCTR2500114659Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trametinib in Neoplasm, glioma, plexiform neurofibroma (PN) and 10 more, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective Response Rate (ORR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trametinib
03
Conditions
Neoplasmgliomaplexiform neurofibroma (PN)Langerhans cell histiocytosis (LCH)neuroblastoma
Beyond the preview
Go deeper on ChiCTR2500114659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114659.